Involvement of microRNAs in HER2 signaling and trastuzumab treatment

Mao, Ling; Sun, Aijun; Wu, Jianzhong; Tang, Jinhai

doi:10.1007/s13277-016-5405-3

Cited by 16 publications

(13 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, the key biological functions of lncRNA to malignancies are possibly oncogenic or tumor suppressive mediated by microRNAs (miRNAs). 2,25 This hypothesis provides a theoretical basis for developing a new treatment of malignancies. By intentionally downregulating lncRNAs, tumor progression or cell growth could be inhibited.…”

Section: Discussionmentioning

confidence: 99%

Biological function of long noncoding RNAsnaRin HER2-positive breast cancer cells

et al. 2017

View full text Add to dashboard Cite

Purpose: Long noncoding RNA, snaR (small NF90-associated RNA), has been reported to be upregulated in various cancer cell lines. We evaluated the additional role of snaR in HER2-positive breast cancer cell lines. Methods: We explored changes of expression of snaR among the selected long noncoding RNAs which have a potential in cancer proliferation or progression. The proliferation, migration, and invasion of HER2-positive breast cancer cells (SK-BR3) were evaluated by snaR with RNA interruption in 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide, wound-healing assay, and Transwell assay. Results: The expression of snaR was remarkably upregulated in SK-BR3 cell lines together with ANRIL, while the SFMBT2 was downregulated in SK-BR3 cell lines. Although Nespas, 7SK, PSF inhibiting RNA, mascRNA, Hoxa11as, NRON, AK023948, MER11C, p53 mRNA, CAR Intergenic 10, HUC 1 and 2, ZFAS1, SCA8, and SNHG5 were also upregulated and UCA1 was downregulated, the differences were not dominent. Based on the expression result, we explored the functional role of snaR in HER2-positive breast cancer. Downregulation of snaR with small interfering RNA was identified to significanlty inhibit migration as well as proliferation of SK-BR3 cells. Conclusion: In this study, snaR was identified as upregulated and to play a role in cancer progression of HER2-positive breast cancer cells. These results suggest snaR as a potential biomarker for HER2-positive breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Biological function of long noncoding RNAsnaRin HER2-positive breast cancer cells

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Preclinical studies have suggested that activation of alternative tyrosine kinase receptors (such as EGFR, HER3, FGFR2 and MET) or signaling pathways (such as Src and Notch1), often leading to epithelial-mesenchymal transition, could lead to secondary resistance to trastuzumab [ 27 ]. Micro RNAs have also been pointed out as a potential actor in primary and secondary resistance to HER2-targetting therapy [ 28 ]. Moreover, the direct loss of HER2 overexpression or amplification have been reported after exposition to trastuzumab containing therapy [ 29 , 30 ], raising the question of the interest of new biopsies at disease progression.…”

Section: Discussionmentioning

confidence: 99%

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study

et al. 2017

View full text Add to dashboard Cite

IntroductionTrastuzumab in combination with platinum-based chemotherapy is the standard first-line regimen in HER2-positive advanced gastric cancer. However, there are very few data concerning efficacy of continuing trastuzumab beyond first-line progression.MethodsThis retrospective multicenter study included all consecutive patients with HER2-positive advanced gastric or gastro-esophageal junction (GEJ) adenocarcinoma who received a second-line of chemotherapy with or without trastuzumab after progression on platinum-based chemotherapy plus trastuzumab. Progression-free survival (PFS) and overall survival (OS) were estimated from the start of second-line chemotherapy using the Kaplan-Meier method and compared using log-rank test. The prognostic variables with P values ≤ 0.05 in univariate analysis were eligible for the Cox multivariable regression model.ResultsFrom May 2010 to December 2015, 104 patients were included (median age, 60.8 years; male, 78.8%; ECOG performance status [PS] 0-1, 71.2%). The continuation (n=39) versus discontinuation (n=65) of trastuzumab beyond progression was significantly associated with an improvement of median PFS (4.4 versus 2.3 months; P=0.002) and OS (12.6 versus 6.1 months; P=0.001. In the multivariate analysis including the ECOG PS, number of metastatic sites and measurable disease, the continuation of trastuzumab beyond progression remained significantly associated with longer PFS (HR, 0.56; 95% CI, 0.35-0.89; P=0.01) and OS (HR, 0.47; 95% CI, 0.28-0.79; P=0.004).ConclusionThis study suggests that continuation of trastuzumab beyond progression has clinical benefit in patients with HER2-positive advanced gastric cancer. These results deserve a prospective randomized validation.

show abstract

“…Currently, a promising strategy for breast cancer is the development of novel therapeutic targets, many of which have been studied extensively in preclinical and clinical models [ 2 ]. Trastuzumab, for example, is the first anti-HER2 (human epidermal growth factor receptor 2) monoclonal antibody applied in systemic adjuvant therapy for patients with HER2-positive breast cancer, with significant benefits in BC treatment [ 3 ]. Therefore, the identification of the molecular markers for prognosis is important in benefiting BC patients.…”

Section: Introductionmentioning

confidence: 99%

Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer

Shi

Cai

et al. 2017

Oncotarget

View full text Add to dashboard Cite

SYF2, a known cell cycle regulator, is reported to be involved in cell cycle arrest by interacting with cyclin-D-type binding protein 1. In the present study, we investigated the role of SYF2 in human breast cancer (BC) progression. SYF2 was highly upregulated in BC tissues and cell lines, as per Western blot and immunohistochemistry analysis. The SYF2 expression level had a significant correlation with the tumor grade and Ki-67 expression. In vitro starvation-refeeding experiment and SYF2-siRNA transfection assay demonstrated that SYF2 could promote proliferation of BC cells, while SYF2 knockdown resulted in cells cycle arrest at G1/S phase, reducing the cell growth rate of BC cells. These results indicated that SYF2 promotes human BC progression by accelerating the BC cells’ proliferation. SYF2 could be a novel therapeutic target in human BC therapies.

show abstract

Involvement of microRNAs in HER2 signaling and trastuzumab treatment

Cited by 16 publications

References 84 publications

Biological function of long noncoding RNAsnaRin HER2-positive breast cancer cells

Biological function of long noncoding RNAsnaRin HER2-positive breast cancer cells

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study

Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer

Contact Info

Product

Resources

About